Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Healthcare Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Healthcare Ventures

Healthcare Ventures

Operating

Healthcare Ventures LLC: A Massachusetts-based venture capital firm investing in early-stage life science companies.

Location
Cambridge, MA, US
Founded
1995
Firm
Compare
Portfolio
Employees
Website

Investments

Galleon Pharmaceuticals
Galleon Pharmaceuticals
Acquired

Total Raised

$53M

Rounds

8

Series B$10MJune 2015
Pathogenetix
Pathogenetix

Total Raised

$28.4M

Rounds

6

Series C$10MOctober 2013
Series B$7.5MNovember 2011
Series B$4MAugust 2011
Series A$4.4MJuly 2008
Theraclone Sciences
Theraclone Sciences

Total Raised

$63.2M

Rounds

8

Series B$8MMarch 2013
Series B$10.6MSeptember 2011
Series Unknown$1.5MMarch 2010
Series B$29MMarch 2007
DecImmune Therapeutics
DecImmune Therapeutics

Total Raised

$8.4M

Rounds

3

Series Unknown$2.3MFebruary 2013
Series Unknown$3.2MSeptember 2010
Gitr
Gitr

Total Raised

$4.8M

Rounds

4

Series Unknown$1MJune 2012
Mosaic Biosciences
Mosaic Biosciences

Total Raised

$14.7M

Rounds

3

Series A$1MNovember 2011
Apellis Pharmaceuticals
Apellis Pharmaceuticals
Public

Total Raised

$168.5M

Rounds

11

Series A$3MJune 2011
Anchor Therapeutics
Anchor Therapeutics
Acquired

Total Raised

$29M

Rounds

2

Series B$10MAugust 2010
Trevena
Trevena
Public

Total Raised

$473.7M

Rounds

18

Series B$35MJuly 2010
Series A$24MMarch 2008
Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals
Acquired

Total Raised

$307.9M

Rounds

5

Series Unknown$87.8MOctober 2009
Series A$25MJuly 2007
Series A$170MJuly 2005
Anexon
Anexon

Total Raised

$7.5M

Rounds

2

Seed$500kDecember 2007
Ascent Therapeutics
Ascent Therapeutics

Total Raised

$19M

Rounds

1

Series A$19MNovember 2007
Sequoia Pharmaceuticals
Sequoia Pharmaceuticals
Acquired

Total Raised

$60.8M

Rounds

3

Series C$35MJanuary 2007
Series B$22MMarch 2005
Globeimmune
Globeimmune
Acquired

Total Raised

$128.5M

Rounds

10

Series B$34.3MDecember 2005